These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 20840438)
1. Testing new drugs in naked apes and getting the dose right in their young. Ritter JM Br J Clin Pharmacol; 2010 Oct; 70(4):467-70. PubMed ID: 20840438 [No Abstract] [Full Text] [Related]
3. Getting the Dose Right: report from the Tenth European Federation of Pharmaceutical Sciences (EUFEPS) conference on optimizing drug development. Stanski DR; Rowland M; Sheiner LB J Pharmacokinet Pharmacodyn; 2005 Apr; 32(2):199-211. PubMed ID: 16283539 [TBL] [Abstract][Full Text] [Related]
4. [The current requirements for the preclinical study of the safety of new drugs]. Arzamastsev EV; Liubimov BI Eksp Klin Farmakol; 1995; 58(3):7-12. PubMed ID: 7663306 [No Abstract] [Full Text] [Related]
5. To scale or not to scale: the principles of dose extrapolation. Sharma V; McNeill JH Br J Pharmacol; 2009 Jul; 157(6):907-21. PubMed ID: 19508398 [TBL] [Abstract][Full Text] [Related]
8. Single dose toxicity and repeated dose toxicity studies: introductory remarks. Kurokawa Y; Matsuzawa T J Toxicol Sci; 1996 Dec; 21(5):413-6. PubMed ID: 9035047 [No Abstract] [Full Text] [Related]
9. Microdosing for reduction of the time and resources for drug development. Sudo K Drug Metab Pharmacokinet; 2007 Oct; 22(5):327. PubMed ID: 17965515 [No Abstract] [Full Text] [Related]
11. The minimum anticipated biological effect level (MABEL) for selection of first human dose in clinical trials with monoclonal antibodies. Muller PY; Milton M; Lloyd P; Sims J; Brennan FR Curr Opin Biotechnol; 2009 Dec; 20(6):722-9. PubMed ID: 19896825 [TBL] [Abstract][Full Text] [Related]
12. [Methodological characteristics of the preclinical study of the safety of drug preparations for children]. Mal'tseva LF; Muratova GP; Motovilova VG; Sirinova NA Farmakol Toksikol; 1988; 51(4):96-100. PubMed ID: 3191987 [TBL] [Abstract][Full Text] [Related]
13. Plasma protein binding and blood-free concentrations: which studies are needed to develop a drug? Pellegatti M; Pagliarusco S; Solazzo L; Colato D Expert Opin Drug Metab Toxicol; 2011 Aug; 7(8):1009-20. PubMed ID: 21635153 [TBL] [Abstract][Full Text] [Related]
14. "Getting the dose right": facts, a blueprint, and encouragements. Peck CC; Cross JT Clin Pharmacol Ther; 2007 Jul; 82(1):12-4. PubMed ID: 17571068 [No Abstract] [Full Text] [Related]
15. Orphan drug development is not taking off. Joppi R; Bertele V; Garattini S Br J Clin Pharmacol; 2009 May; 67(5):494-502. PubMed ID: 19552743 [No Abstract] [Full Text] [Related]
16. High dose selection in general toxicity studies for drug development: A pharmaceutical industry perspective. Buckley LA; Dorato MA Regul Toxicol Pharmacol; 2009 Aug; 54(3):301-7. PubMed ID: 19477212 [TBL] [Abstract][Full Text] [Related]
17. Pharmacology and safety assessment of humanized monoclonal antibodies for therapeutic use. Klingbeil C; Hsu DH Toxicol Pathol; 1999; 27(1):1-3. PubMed ID: 10367664 [TBL] [Abstract][Full Text] [Related]
18. Special anniversary volume -- issue 4: replacement -- focus on the development of therapeutics. Preface. Balls M Altern Lab Anim; 2009 Sep; 37(4):353-4. PubMed ID: 19916255 [No Abstract] [Full Text] [Related]
19. Drug Development of Therapeutic Monoclonal Antibodies. Mould DR; Meibohm B BioDrugs; 2016 Aug; 30(4):275-93. PubMed ID: 27342605 [TBL] [Abstract][Full Text] [Related]
20. [Monoclonal antibodies and the targeting of drugs]. Couvreur P J Pharm Belg; 1984; 39(4):249-54. PubMed ID: 6512669 [No Abstract] [Full Text] [Related] [Next] [New Search]